|Mr. John A. Kollins||Pres, CEO & Director||558.59k||N/A||1963|
|Mr. Thomas P. O'Neil||Chief Financial Officer||475.18k||N/A||1965|
|Dr. Detlef F. Albrecht||Chief Medical Officer||483.2k||N/A||1961|
|Mr. Mic Iwashima||VP & Head of Operations||N/A||N/A||1978|
|Mr. Robert Schultz||VP & Head of CMC||N/A||N/A||1964|
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.